About Secretome Therapeutics
Secretome Therapeutics is a Healthcare company based in Dallas (United States) founded in 2018 by Sunjay Kaushal. Cell-based therapies for multiple diseases are developed. Secretome Therapeutics has raised $52.15 million across 4 funding rounds from investors including Parent Project Muscular Dystrophy and RA Capital. Its chief executive, as recorded, is Vinny Jindal. Secretome Therapeutics offers products and services including STM-01 and STM-21. Its focus areas include Life Sciences, Nephrology, Drugs and Chronic Kidney Diseases. Its legal entity is Secretome Therapeutics, Inc. Its competitors include AskBio, Unicycive and Akebia Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Secretome Therapeutics was founded in 2018 in Dallas, United States, within the biotechnology sector. Cell-based therapies targeting various diseases are developed, with operations focused on innovative treatments. Lead products include STM-21, designed to prevent inflammatory toxicities from cancer therapies like cisplatin-induced acute kidney injury, and STM-01, a therapy using neonatal mesenchymal stem cells to restore cardiac function following heart attacks.
- Headquarters Dallas, United States
- Founders Sunjay Kaushal
- SectorsHealthcare
- Phone•••• ••••
- Website secretometherapeutics.com
- Social LinkedIn
- Legal Name Secretome Therapeutics, Inc
- Total Equity Funding$52.15M (USD)
in 4 rounds
- Latest Funding Round$30M (USD), Series A
May 2026
- InvestorsParent Project Muscular Dystrophy
& 1 more
Products & Services of Secretome Therapeutics
Secretome Therapeutics offers a comprehensive portfolio of products and services, including STM-01 and STM-21.
Drug derived from nCPCs for treating heart failure and related conditions.
Secretome from nCPCs aimed at regenerative cardiovascular therapies.
Funding Insights of Secretome Therapeutics
Secretome Therapeutics has successfully raised a total of $52.15M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $30 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $52.15M
- Total Rounds 4
- Last Round Series A — $30M
- First Round $1.5M
(Oct 2019)
- Investors Count 2
All 4 funding rounds of Secretome Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $30M | Series A | – | RA Capital Management | – |
| Mar 2026 | $250,000 | Series B | – | – | |
| Nov 2024 | $20.4M | Series B | – | – | – |
| Oct 2019 | $1.5M | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Secretome Therapeutics
Secretome Therapeutics has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Parent Project Muscular Dystrophy and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| parentprojectmd.org | ||||
| racap.com |
Investor details for Secretome Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Secretome Therapeutics
13 people are tracked at Secretome Therapeutics (5 in leadership, 8 in board & advisors).
| Name | Role | Group |
|---|---|---|
Sunjay Kaushal | Founder | Leadership |
Vinny Jindal | CEO | Leadership |
Jeff Masten | Chief Technical Officer | Leadership |
Malika Pasha | Vice President Clinical Operations | Leadership |
Jamie Niland | Vice President, Operations | Leadership |
Bill Niland | Director | Board & advisors |
Henrik Rasmussen | Director | Board & advisors |
Angela Shen | Director | Board & advisors |
Javed Butler | Scientific Advisory Board Member | Board & advisors |
Shruti Gupta | Scientific Advisory Board Member | Board & advisors |
Kenar D. Jhaveri | Scientific Advisory Board Member | Board & advisors |
Mark A. Perazella | Scientific Advisory Board Member | Board & advisors |
Mitch Rosner | Scientific Advisory Board Member | Board & advisors |
Complete people profiles for Secretome Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Secretome Therapeutics
3 dated milestones of Secretome Therapeutics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Secretome Therapeutics is founded.
- Funding First funding round of $1.5M.
- Funding Latest funding round, Series A, of $30.0M.
Competitors of Secretome Therapeutics
Secretome Therapeutics has 3 listed competitors in our database, 3 of them funded. They include AskBio, Unicycive and Akebia Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| askbio.com | 2001 | Durham, United States | $235M | Gene and protein therapies are developed for treating various diseases. | ||
| unicycive.com | 2016 | San Francisco, United States | $1.55M | 12 | Small molecule therapies for kidney diseases are developed. | |
| akebia.com | 2007 | Cincinnati, United States | $91M | 205 | Therapeutics for kidney disease treatment are developed by Akebia Therapeutics. |
Detailed competitors of Secretome Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cell Therapy
3 companies that operate in the same segment as Secretome Therapeutics (Cell Therapy) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | 520 | ||
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 233 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Secretome Therapeutics
Complete news archive for Secretome Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Secretome Therapeutics
Secretome Therapeutics was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Secretome Therapeutics is headquartered in Dallas, United States. It is registered at Dallas, Texas, United States.
Vinny Jindal is the CEO of Secretome Therapeutics, as recorded in our data.
Secretome Therapeutics is a funded company, having raised a total of $52.15M across 4 funding rounds to date. The company's 1st funding round was a Seed of $1.5M, raised on Oct 2019.
Secretome Therapeutics was founded in 2018 in Dallas, United States, within the biotechnology sector. Cell-based therapies targeting various diseases are developed, with operations focused on innovative treatments. Lead products include STM-21, designed to prevent inflammatory toxicities from cancer therapies like cisplatin-induced acute kidney injury, and STM-01, a therapy using neonatal mesenchymal stem cells to restore cardiac function following heart attacks.
Secretome Therapeutics's top competitors include AskBio, Akebia Therapeutics and Unicycive.
Secretome Therapeutics offers STM-01 and STM-21.
Secretome Therapeutics has 2 investors. Key investors include Parent Project Muscular Dystrophy, and RA Capital.
Secretome Therapeutics operates through Secretome Therapeutics, Inc.